Opus Genetics, Inc.
LCA5
inherited retinal disease
Countdown
542days
Phase 3 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 3 trial results for LCA5 in inherited retinal disease are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Clinical development timelines are based on current estimates and are subject to change; data readouts are targeted for ~9-12 months after study initiation.”